An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes

Bibliography

• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8
   PubMed Web of Science ®Google Scholar
• Lo JC, Mulligan K, Tai VW, et al. “Buffalo hump” in men with HIV-1 infection. Lancet 1998;351:867-70
   PubMed Web of Science ®Google Scholar
• Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998;351:871-5
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13(13):1657-67
   Google Scholar
• Heath KV, Hogg RS, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002;30:440-7
   PubMed Web of Science ®Google Scholar
• Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipolCoNa Study. Arch Intern Med 2002;162:2621-8
   PubMed Web of Science ®Google Scholar
• Law, M, Puls R, Cheng AK, et al. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther 2006;11(2):179-86
   PubMedGoogle Scholar
• Barata A, Malouf J, Gutierrez M, et al. Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy. Braz J Infect Dis 2013;17(4):444-9
   PubMedGoogle Scholar
• Nachega JB, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep 2009;6(3):121-9
   PubMedGoogle Scholar
• Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10
   PubMed Web of Science ®Google Scholar
• Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003
   PubMed Web of Science ®Google Scholar
• Varriale P, Saravi G, Hernandez E, et al. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 2004;147:55-9
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62
   PubMed Web of Science ®Google Scholar
• DAD Study Group. Friss-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356(17):1723-35
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003;361:726-35
   PubMed Web of Science ®Google Scholar
• Pérez-Matute P, Pérez-Martínez L, Blanco JR, et al. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013:493413
   PubMedGoogle Scholar
• Podzamczer D, Ferrer E, Martínez E, et al. How much fat loss is needed for lipoatrophy to become clinically evident. AIDS Res Hum Retroviruses 2009;25:563-7
   PubMed Web of Science ®Google Scholar
• Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40:121-31
   PubMed Web of Science ®Google Scholar
• Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomised trial. J Acquir Immune Defic Syndr 2006;41(5):590-7
   PubMed Web of Science ®Google Scholar
• Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007;21:1731-8
   PubMed Web of Science ®Google Scholar
• De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013;8(5):e63623
   PubMed Web of Science ®Google Scholar
• Smith D, Hudson J, Martin A, et al. Centralized assessment of dual-energy x-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy. HIV Clin Trials 2003;4:45-9
   PubMed Web of Science ®Google Scholar
• Milinkovic A, Vidal S, Bianchi L, et al. Comparative assessment of objective methods for the measurement of body fat. Antivir Ther 2003;8:L63
   Google Scholar
• Vidal F, Gutierrez F, Gutierrez M, et al. Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 2010;12:15-30
   PubMed Web of Science ®Google Scholar
• Viladés C, Escoté X, López-Dupla M, et al. Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). J Antimicrob Chemother 2014;69(6):1653-9
   PubMedGoogle Scholar
• Domingo P, Mateo MG, Pruvost A, et al. Polymorphisms of pyrimidine pathway enzymes encoding genes and HLA-B*40 01 carriage in stavudine-associated lipodystrophy in HIV-infected patients. PLoS One 2013;8(6):e67035
   PubMedGoogle Scholar
• Giralt M, Domingo P, Guallar J, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006;11:729-40
   PubMed Web of Science ®Google Scholar
• Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16(18):2447-54
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation on the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 2003;17:971-9
   PubMed Web of Science ®Google Scholar
• Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19(16):1807-18
   PubMedGoogle Scholar
• Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003;17:1329-38
   PubMed Web of Science ®Google Scholar
• Feeney ER, van Vonderen MG, Wit F, et al. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS 2012;26(17):2165-74
   PubMedGoogle Scholar
• Pace CS, Martin AM, Hammond EL, et al. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003;8:323-31
   PubMed Web of Science ®Google Scholar
• Sievers M, Walker U, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 2009;200:252-62
   PubMed Web of Science ®Google Scholar
• Hadigan C, Borgonha S, Rabe J, et al. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002;51:1143-7
   PubMed Web of Science ®Google Scholar
• Law M, Puls R, Cheng A, et al. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naïve adults. Antivir Ther 2006;11:179-86
   PubMed Web of Science ®Google Scholar
• Tebas P, Sension M, Arribas J, et al. Analysis of lipid levels and changes in body fat distribution in treatment-naive, HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-18
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011;53(2):185-96
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53(8):807-16
   PubMed Web of Science ®Google Scholar
• Díaz-Delfín J, Del Mar G, Gallego-Escuredo J, et al. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res 2011;91:112-19
   PubMed Web of Science ®Google Scholar
• Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, et al. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010;8(7):545-53
   PubMed Web of Science ®Google Scholar
• Díaz-Delfín J, Domingo P, Mateo MG, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother 2012;56(6):3369-75
   PubMedGoogle Scholar
• Van Der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55
   PubMed Web of Science ®Google Scholar
• Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-88
   PubMed Web of Science ®Google Scholar
• Del Mar Gutierrez M, Mateo MG, Vidal F, et al. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf 2014;13(4):431-45
   PubMed Web of Science ®Google Scholar
• Katlama C, Assoumou L, Valantin MA, et al. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. J Antimicrob Chemother 2014. [ Epub ahead of print]
   Google Scholar
• Guaraldi G, Fontdevila J, Christensen LH, et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011;25(1):1-12
   PubMedGoogle Scholar
• Hultman CS, McPhail LE, Donaldson JH, Wohl DA. Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy. Ann Plast Surg 2007;58(3):255-63
   PubMedGoogle Scholar
• Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naïve patients randomized to a didanosine and stavudine versus abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38:147-55
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201
   PubMed Web of Science ®Google Scholar
• Dubé M, Parker R, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomised to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44(2):139-47
   PubMed Web of Science ®Google Scholar
• Gallant JE, De Jesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60
   PubMed Web of Science ®Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013;29:256-65
   PubMed Web of Science ®Google Scholar
• Martin A, Moore CL, Mallon PWG, et al. HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One 2013;8(10):e77138
   PubMedGoogle Scholar
• Domingo P, Estrada V, López-Aldeguer J, et al. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev 2012;14(2):112-23
   PubMed Web of Science ®Google Scholar
• Martinez E, Estany C, Negredo E. Morphologic changes 42 months after antiretroviral treatment interruption [abstract P66]. Proceedings of the Eighth International Congress on Drug Therapy in HIV Infection; Glasgow, UK; 2006
   Google Scholar
• Martinez E, Milinkovic A, Garcia F, et al. Greater limb fat increase with intermittent (relative to continuous) thimidine-sparing antiretroviral therapy in HIV-infected patients with lipoatrophy. Antivir Ther 2008;13:A9
   PubMedGoogle Scholar
• Martinez E, Visnegarwala F, Grund B, et al. The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. AIDS 2010;24(3):353-63
   PubMedGoogle Scholar
• El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355(22):2283-96
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS 2004;18:1029-36
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22-8
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogues in patients with HIV lipoatrophy: a randomised trial. JAMA 2002;288:207-15
   PubMed Web of Science ®Google Scholar
• McComsey G, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodefiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004;38:263-70
   PubMed Web of Science ®Google Scholar
• Zhong L, Cotton G, Enejosa J. Improvement in lipoatrophy and lipid abnormalities following switch from stavudine (d4T) to tenofovir (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-infected patients: a 48-week follow-up from study [abstract 64L40]. Proceedings of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Dublin, Ireland; 2005
   Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al. A randomised comparative trial of tenofovir DF or abacavir as replacement for a thimidine analogue in persons with lipoatrophy. AIDS 2006;20(16):2043-50
   PubMed Web of Science ®Google Scholar
• Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009;51(5):562-8
   PubMed Web of Science ®Google Scholar
• Tebas P, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. J Antimicrob Chemother 2009;63(5):998-1005
   PubMedGoogle Scholar
• Bernardino JI, Pulido F, Martinez E, et al. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother 2013;68(6):1373-81
   PubMedGoogle Scholar
• Valantin MA, Flandre P, Kolta S, et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks [abstract 721]. Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; 2010
   Google Scholar
• Guaraldi G, Zona S, Cossarizza A, et al. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. Int J STD AIDS 2014;25(3):207-12
   PubMed Web of Science ®Google Scholar
• Domingo P, Gutierrez M del M, Gallego-Escuredo JM, et al. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. PLoS ONE 2014;9(2):e89088
   PubMedGoogle Scholar
• John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33(1):29-33
   PubMedGoogle Scholar
• Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12(3):407-15
   PubMed Web of Science ®Google Scholar
• Carr A, Hudson J, Chau J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, controlled, open-label, multcentre study. AIDS 2001;15:1811-22
   PubMed Web of Science ®Google Scholar
• Tavassoli N, Bagueri H, Sommet A, et al. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy s-ray absorptiometry. Pharmacotherapy 2006;26(2):154-61
   PubMedGoogle Scholar
• Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36
   PubMed Web of Science ®Google Scholar
• Estrada V, De Villar N. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002;35:69-76
   PubMed Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamcer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-46
   PubMed Web of Science ®Google Scholar
• Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19(9):917-25
   PubMed Web of Science ®Google Scholar
• Edgeworth A, Treacy MP, Hurst TP. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. AIDS Rev 2013;15(3):171-80
   PubMedGoogle Scholar
• Sheth SH, Larson RJ. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010;10:183
   PubMedGoogle Scholar
• Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 2010;24(9):1291-8
   PubMedGoogle Scholar
• Bell DS, Patil HR, O’Keefe JH. Divergent effects of various diabetes drugs on cardiovascular prognosis. Rev Cardiovasc Med 2013;14(2-4):e107-22
   PubMedGoogle Scholar
• Slama L, Lanoy E, Valanin MA, et al. Effect of pioglitazone on HIV-1 related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113) Antivir Ther. 2008;13:67-76
   Google Scholar
• Raboud JM, Diong C, Carr A, et al. A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy. HIV Clin Trials 2010;11(1):39-50
   PubMed Web of Science ®Google Scholar
• Mallon P, Miller J, Kovacic K. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men–a randomized, placebo-controlled study. AIDS 2006;20(7):1003-10
   PubMed Web of Science ®Google Scholar
• Calmy A, Bloch M, Wand H, et al. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010;11(8):493-501
   PubMedGoogle Scholar
• Walker U, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005;10(Suppl 2):M117-23
   PubMedGoogle Scholar
• Banasch M, Goetze O, Knyhala K, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patient. AIDS 2006;20(11):1554-6
   PubMed Web of Science ®Google Scholar
• Walker U, Auclair M, Lebrecht D, et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006;11(1):25-34
   PubMedGoogle Scholar
• Sutinen J, Walker U, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther 2007;12:97-105
   PubMed Web of Science ®Google Scholar
• McComsey GA, Walker UA, Budhathoki CB, et al. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS 2010;24(16):2507-15
   PubMedGoogle Scholar
• McComsey GA, O’Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther 2012;17(2):347-53
   PubMed Web of Science ®Google Scholar
• Moyle G, Moutschen M, Martínez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010;12(1):3-14
   PubMedGoogle Scholar
• Moyle GJ, Andrade-Villanueva J, Girard PM, et al. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther 2012;17(4):689-700
   PubMedGoogle Scholar
• Ferrer E, del Rio L, Martínez E, et al. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. AIDS Res Hum Retroviruses 2011;27(10):1061-5
   PubMedGoogle Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012;26(4):475-81
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitors. AIDS 1999;13:1000-2
   PubMed Web of Science ®Google Scholar
• Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomised controlled trial. JAMA 2000;284:472-7
   PubMed Web of Science ®Google Scholar
• Martinez E, Domingo P, Ribera E, et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther 2003;8:403-10
   PubMed Web of Science ®Google Scholar
• Snel Y, Brummer R, Doerga M, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone deficient adults: the effect of growth hormone replacement and a comparison with control subject. Am J Clin Nutr 1995;61:1290-4
   PubMed Web of Science ®Google Scholar
• Lönn L, Johannsson G, Sjöström L, et al. Body composition and tissue distribution in growth hormone deficient adults before and after growth hormone treatment. Obes Res 1996;4:45-54
   PubMedGoogle Scholar
• De Boer H, Blok G, Voerman B, et al. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men. Int J Obes Relat Metab Disord 1996;20:580-7
   PubMed Web of Science ®Google Scholar
• Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 2001;86:504-10
   PubMed Web of Science ®Google Scholar
• Koutkia P, Meininger G, Canavan B, et al. Metabolic regulation of growth hormone by free fatty acids, somatostatine, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E296-303
   PubMedGoogle Scholar
• Torres RA, Unger KW, Cadman JA, et al. Recombinant human growth hormone improves truncal adiposity and “buffalo humps” in HIV-positive patients on HAART [letter]. AIDS 1999;13:2479-81
   PubMed Web of Science ®Google Scholar
• Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103
   PubMed Web of Science ®Google Scholar
• Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001;86:3480-7
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004;35(3):239-52
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr 2007;45(3):286-97
   PubMedGoogle Scholar
• Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 2002;30:379-91
   PubMed Web of Science ®Google Scholar
• Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87:942
   PubMed Web of Science ®Google Scholar
• Deodati A, Ferroli BB, Cianfarani S. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: systematic review and meta-analysis. Growth Horm IGF Res 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 2008;300(5):509-19
   PubMedGoogle Scholar
• Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005;19:1279-87
   PubMed Web of Science ®Google Scholar
• Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-304
   PubMedGoogle Scholar
• Mateo G, Gutierrez M, Domingo P. Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy. Expert Rev Endocrinol Metab 2011;6(1):21-30
   PubMedGoogle Scholar
• Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16:991-7
   PubMed Web of Science ®Google Scholar
• Marin P, Krotkiewski M, BJorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992;1:329-36
   PubMedGoogle Scholar
• Bhasin S. Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression. Clin Infect Dis 2003;37(Suppl 2):S142-9
   PubMedGoogle Scholar
• Marin P, Lonn L, Andersson B, et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab 1996;81:1018-22
   PubMed Web of Science ®Google Scholar
• Seidell JC, Bjorntorp P, Sjostrom L, et al. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990;39:897-901
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha VK, Dwyer AA, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005;28:1636-42
   PubMed Web of Science ®Google Scholar
• Kappor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycemic control, visceral adiposity, and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:889-906
   Google Scholar
• Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab 2007;92(3):1049-57
   PubMed Web of Science ®Google Scholar
• Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1(11):1155-61
   PubMed Web of Science ®Google Scholar
• Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269(5223):543-6
   PubMed Web of Science ®Google Scholar
• Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004;89(10):4821-6
   PubMed Web of Science ®Google Scholar
• Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-44
   PubMed Web of Science ®Google Scholar
• Lee JH, Chan JL, Sourlas E, et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91(7):2605-11
   PubMed Web of Science ®Google Scholar